Nautilus Biotechnology Announces Baylor College of Medicine as First Early Access Program Customer for Voyager Platform Nautilus Biotechnology (NASDAQ: NAUT) named Baylor College of Medicine its first customer for the Iterative Mapping Early Access Program on March 18, 2026. Baylor will use the Nautilus Voyager™ Platform in an NIH U01-funded study to develop a computational multi-omics toolkit for high-resolution cancer isoform analysis.The collaboration pairs Baylor’s computational expertise with Nautilus’ single-molecule proteomics and validated tau proteoforms assay to improve detection and quantification of protein isoforms and enable direct transcriptional–proteomic comparisons.

#NAUT Nautilus Biotechnology Announces Baylor College of Medicine as First Early Access Program Customer for Voyager Platform

www.stocktitan.net/news/NAUT/nautilus-biote...

Nautilus Biotechnology Reports Fourth Quarter and Fiscal Year 2025 Financial Results Nautilus Biotechnology (NASDAQ: NAUT) reported Q4 and fiscal 2025 results on Feb 26, 2026. Operating expenses fell to $15.4M in Q4 and $66.8M for FY2025, while net loss was $13.8M in Q4 and $59.0M for FY2025. Cash and investments totaled $156.1M as of Dec 31, 2025.The company launched an Iterative Mapping Early Access Program in Jan 2026, advanced platform validation with Tau proteoform data, and initiated a Michael J. Fox Foundation–supported collaboration for alpha-synuclein assays. Nautilus expects no material Early Access revenue in 2026 and forecasts operating expense growth of 15–20% year over year, believing cash suffices to fund operations through 2027.

#NAUT Nautilus Biotechnology Reports Fourth Quarter and Fiscal Year 2025 Financial Results

www.stocktitan.net/news/NAUT/nautilus-biote...

Leading Indicators, Thursday November 13, 2025 – Crystal Equity Research

Small-cap stocks with improving money flow, Thu Nov 13th - #CREX #KROS #ZBIO #SHIP #ROOT #PLUS #NAUT #MESA #GECC #CCII #AMAL #NCDL #MFA #HGTY #FPH #EB - More: crystalequityresearch.com/leading-indi... - #smallcap

#NAUT Nautilus Biotechnology Reports Successful Installation and Testing of its First Field Evaluation Unit at the Buck Institute for Research on Aging

www.stocktitan.net/news/NAUT/nautilus-biote...

NAUT: "Any art is a mirror!" | Interview @ Bats In The Attic 2025
youtu.be/lyS63BtlMn0?...

#naut #nautuk #postpunk #rock #goth #gothic #classicrock #drummachinerock #batsintheattic #morecambe #mcgothicfoxpromotions #england #nightshade #nghtshadetv #nightshademaggazin

Breaking News: ( NASDAQ: #NAUT ) Expected US Company Earnings on Tuesday, October 28th, 2025

Nautilus Biotechnology Reports Third Quarter 2025 Financial Results Nautilus Biotechnology (NASDAQ: NAUT) reported third quarter 2025 results for the period ended September 30, 2025. Key operational milestones include continued processing of Tau proteoform samples with collaborators and progress on a broadscale assay format intended to support a commercial launch in late 2026. The company expects an early access program for Tau proteoforms in the first half of 2026 and plans to share collaborator data at the upcoming World HUPO conference.Financial highlights: Operating expenses were $15.5 million in Q3 2025, down 19% year-over-year; net loss was $13.6 million versus $16.4 million a year earlier; and cash, cash equivalents, and investments totaled $168.5 million as of September 30, 2025. A conference call and webcast were scheduled for October 28, 2025 at 5:30 AM PT.

#NAUT Nautilus Biotechnology Reports Third Quarter 2025 Financial Results

www.stocktitan.net/news/NAUT/nautilus-biote...

Confira o nosso review de Katanut! Jogamos em antecipado este roguelite insano que traz a história do guerreiro solitário Naut!

buff.ly/HC1sL37

#análise #games #jogos #naut #novidades #review

Trade Alerts, Tuesday September 9, 2025 – Crystal Equity Research

Small-cap stocks registering bullish MACD Crossover, Tue Sept 9th - #ECX #USIO #REKR #QUIK #PNTG #NAUT #LGHL #IPSC #GREE - More: crystalequityresearch.com/trade-alerts... - #smallcap

Nautilus Biotech Slashes Costs 18%, Launches Groundbreaking Alzheimer's Research Platform Q2 highlights: Operating costs down 18%, $179.5M cash position, and breakthrough protein analysis platform validated. Two major Alzheimer's research deals signed. See full results.

#NAUT Nautilus Biotechnology Reports Second Quarter 2025 Financial Results

www.stocktitan.net/news/NAUT/nautilus-biote...

Revolutionary Single-Molecule Technology Could Unlock New Alzheimer's Treatment Through Nautilus-Allen Institute Partnership Groundbreaking proteomics partnership aims to decode tau protein's role in Alzheimer's using novel Iterative Mapping technology. Discover potential breakthrough implications.

#NAUT Nautilus Biotechnology Announces Agreement with the Allen Institute, Further Validating its Approach to Single-Molecule Proteomics

www.stocktitan.net/news/NAUT/nautilus-biote...

Nautilus Biotechnology Reports First Quarter 2025 Financial Results Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the first quarter ended March 31, 2025. “In Q1, we saw continued development progress

#NAUT Nautilus Biotechnology Reports First Quarter 2025 Financial Results

www.stocktitan.net/news/NAUT/nautilus-biote...

Nautilus Biotechnology Reports Fourth Quarter and Fiscal Year 2024 Financial Results Nautilus Biotechnology (NASDAQ: NAUT) has released its Q4 and fiscal year 2024 financial results. The company reported Q4 operating expenses of $20.0 million, unchanged from Q4 2023, while full-year operating expenses increased 7% to $81.5 million.Key developments include:Net loss widened to $17.6 million in Q4 2024 and $70.8 million for full-year 2024Cash position stands at $206.3 million as of December 31, 2024Announced 16% workforce reduction to extend cash runwayDelayed launch of proteome analysis platform to late 2026The company expects 2025 operating expenses to be at or below 2024 levels, with current cash reserves projected to sustain operations through 2027.

#NAUT Nautilus Biotechnology Reports Fourth Quarter and Fiscal Year 2024 Financial Results

www.stocktitan.net/news/NAUT/nautilus-biote...

Nautilus Bio Q4 Earnings Alert: Protein Analysis Pioneer Reports Feb 27 Nautilus Biotechnology announces Q4 and full year 2024 earnings release scheduled for February 27, with conference call and webcast to discuss results and business outlook.

#NAUT Nautilus Biotechnology to Announce Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025

www.stocktitan.net/news/NAUT/nautilus-biote...

Tokyo Bay’s Nautical Chart #japan #tokyo #yokosuka #love #tokyobay #naut... youtube.com/shorts/VGCLv... via @YouTube